Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Non Operating Income (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Non Operating Income for 9 consecutive years, with -$117000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 312.73% to -$117000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $58000.0, a 38.3% decrease, with the full-year FY2025 number at $58000.0, down 38.3% from a year prior.
  • Non Operating Income was -$117000.0 for Q4 2025 at Akebia Therapeutics, down from -$10000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.3 million in Q2 2021 to a low of -$117000.0 in Q4 2025.
  • A 5-year average of $329900.0 and a median of $187000.0 in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: skyrocketed 604.35% in 2022, then plummeted 312.73% in 2025.
  • Akebia Therapeutics' Non Operating Income stood at $560000.0 in 2021, then decreased by 22.5% to $434000.0 in 2022, then soared by 51.61% to $658000.0 in 2023, then crashed by 91.64% to $55000.0 in 2024, then tumbled by 312.73% to -$117000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Non Operating Income are -$117000.0 (Q4 2025), -$10000.0 (Q3 2025), and -$28000.0 (Q2 2025).